La vendita allo scoperto per ALX Oncology Holdings dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di ALX Oncology Holdings. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

ALX Oncology Holdings (NASDAQ:ALXO) Azioni, Report sulle vendite allo scoperto

ALX ONCOLOGY HOLDINGS INC

ALX Oncology Holdings

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings Inc

X Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYF#NYSE">XYF</a>) reported quarterly earnings of $1.48 per share. This is a 62.64 percent increase over earnings of $0.91 per share from the same period last year. The company reported $267.00 million in sales this quarter. This is a 59.59 percent increase over sales of $167.30 million the same period last year.

Earnings

News

X Financial Q1 Adj. EPS $1.48 Up From $0.91 YoY, Sales $267.00M Up From $167.30M YoY

GIPR

Trading Halt: Halted at 4:55:00 p.m. ET - Trading Halt: Halt News Pending

<a href="https://asia.nikkei.com/Business/Business-deals/Toyota-group-to-borrow-up-to-21bn-to-take-Toyota-Industries-private">https://asia.nikkei.com/Business/Business-deals/Toyota-group-to-borrow-up-to-21bn-to-take-Toyota-Industries-private</a>

General

'Toyota group to borrow up to $21B to take Toyota Industries private'- Nikkei Asia

Agilysys Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>) reported financial results for the fourth quarter of fiscal 2025 after the market close on Monday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/05/b45505072/agilysys-announces-fiscal-2025-fourth-quarter-record-revenue-of-74-3m-and-full-year-record-revenue">of the report</a>. 
Q4 Earnings: Agilysys reported fourth-quarter revenue of $74.27 million, beating analyst <a href="http://benzinga.com/quote/agys/earnings">estimates</a> of $71.42 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The hospitality software provider reported fourth-quarter earnings of 54 cents per share, beating estimates of 29 cents per share. 
Total revenue increased 19.4% year-over-year as subscription revenue grew 42.7% year-over-year. Recurring revenue grew to a record 62.2% of total net revenue during the quarter. 
Agilysys generated $26.5 million of free cash flow in the quarter and ended the period with approximately $73 million in cash and cash equivalents. 
&#8220;We have had considerable success with our professional services hiring efforts during the recent few months. Fiscal 2025&nbsp;fourth quarter&nbsp;was an excellent period for services implementation execution, driving to record highs both services revenue and annual subscription revenue value of projects installed in the field,&#8221; said Ramesh Srinivasan, president and CEO of Agilysys.
Outlook: Agilysys expects fiscal-year 2026 revenue to be in the range of $308 million to $312 million versus <a href="http://pro.benzinga.com">Benzinga Pro</a> estimates of $318.84 million.
&#8220;This was a transformational year for Agilysys. We managed through operational challenges related to the end stages of the product modernization efforts, completed the acquisition of Book4Time and experienced accelerating sales demand for our modernized cloud-native software ecosystem, &#8221; said Dave Wood, CFO of Agilysys.
&#8220;The record sales year has driven backlog to record levels as we focus on the execution of our FY26 financial plan.&#8221;
Agilysys executives will further discuss the quarter on a conference call with investors and analysts at 4:30 p.m. ET.
AGYS Price Action: <a href="http://benzinga.com/quote/agys">Agilysys shares</a> were up 2.36% after hours, trading at $84.98 at the time of publication Monday, per <a href="http://pro.benzinga.com">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45505333/investors-piled-into-long-term-treasury-etfs-ahead-of-moodys-downgrade-will-confidence-hold">Investors Piled Into Long-Term Treasury ETFs Ahead Of Moody&#8217;s Downgrade: Will Confidence Hold?</a></li>
</ul>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45503979/5-stocks-about-to-short-squeeze-as-market-rebounds">5 Stocks About To Short Squeeze As Market Rebounds</a></li>
</ul>
Photo: Shutterstock.

Guidance

After-Hours Center

Movers

AGYS

Agilysys Reports Better-Than-Expected Q4 Earnings, Shares Move Higher After Hours

WIIM

ASPI

ASP Isotopes shares are trading higher after the company announced it has entered into a loan and supply agreement with TerraPower to support construction of new HALEU uranium enrichment facility in South Africa.

2025 Outlook&nbsp;
The Company has initiated full year 2025 revenue guidance of $521 million to $539 million, reflecting forecasted revenue growth of 18% to 22%. This growth reflects continued demand across the business as many partnerships are in early stages of development.

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

SunCar Tech Gr Sees FY2025 Sales $521.000M-$539.000M vs $533.31M Est

SunCar Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDA#NASDAQ">SDA</a>) reported quarterly losses of $(0.03) per share. This is a 25 percent increase over losses of $(0.04) per share from the same period last year. The company reported $102.59 million in sales this quarter. This is a 19.87 percent increase over sales of $85.59 million the same period last year.

CORRECTION: SunCar Tech Gr Q1 EPS $(0.03) Up From $(0.04) YoY, Sales $102.59M Up From $85.59M YoY

Dakota Gold Corp. (NYSE:<a href="https://www.benzinga.com/stock/DC#NYSE">DC</a>) ("Dakota Gold" or the "Company") is pleased to announce changes to its senior leadership team and Board of Directors. Jack Henris will be appointed President and Chief Operating Officer (COO) of Dakota Gold effective June 1, 2025 upon the retirement of Gerald Aberle, our current COO. Mr. Aberle will continue to serve on the Board of Directors. Todd Kenner and Kevin Puil were appointed to the Board of Directors effective May 15, 2025 and Amy Koenig will resign from the Board of Directors on May 31, 2025 and assume the role of Senior Vice President, Chief Legal Officer and Corporate Secretary for Dakota Gold effective June 1, 2025.

Management

Dakota Gold Appoints Jack Henris As President And COO, Effective June 1, 2025, Upon Retirement Of Gerald Aberle

Offerings

Idaho Strategic Resources Files For Mixed Shelf Of Up To $35M

<ul>
<li>Loan Agreement with TerraPower provides a term loan subject to conditions to support construction of a new uranium enrichment facility at Pelindaba, South Africa. &nbsp;</li>
<li>Supply Agreement supports the supply of HALEU for the first fuel core for TerraPower's Natrium Plant in Wyoming and contemplates the supply of HALEU over a 10-year period. &nbsp;</li>
<li>The Parties have also agreed to explore opportunities for ASPI or its affiliates to work with TerraPower to develop uranium enrichment production facilities within the United States.</li>
</ul>
WASHINGTON, May 19, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that the Company and certain of its subsidiaries have entered into multiple definitive agreements with TerraPower, a US nuclear innovation company, related to financing support for the construction of a new uranium enrichment facility capable of producing High Assay Low-Enriched Uranium (HALEU); and the future supply of HALEU to TerraPower, as a customer.
Loan Agreement
The Loan Agreement provides conditional commitments from TerraPower to the Company through one of its wholly-owned U.S.-based subsidiaries ("Borrower") for a multiple advance term loan to partially finance a proposed new uranium enrichment facility at Pelindaba, South Africa, which is designed to produce commercial quantities of HALEU. The Company is also in discussions with a number of financial institutions to provide additional capital for the construction of this HALEU production facility, and all such additional funding for this facility is expected to be non-dilutive to ASPI shareholders and QLE convertible noteholders.
The Company intends to construct its initial HALEU production facility at Pelindaba, subject to the receipt of all required permits and licenses to begin enrichment of uranium in South Africa. Pelindaba is South Africa's main nuclear research center, the headquarters of Necsa (South African Nuclear Energy Corporation) and is the home of the 20MW research nuclear reactor, SAFARI-1.
The new uranium enrichment facility is designed to produce HALEU with an annual output of approximately 15 MTU of HALEU. The facility is expected to commence initial production of HALEU in 2027, subject to the receipt of all required permits and licenses to begin enrichment of uranium in South Africa, and is anticipated to create hundreds of full-time operational jobs and support thousands of additional jobs across a nationwide manufacturing supply chain. Concurrently, the Company and TerraPower have entered into a mutual commitment to explore further opportunities to develop uranium enrichment production facilities in the United States.
HALEU Supply Agreements
In addition to a loan agreement, the Company and TerraPower have entered into two supply agreements for the HALEU expected to be produced at the Company's uranium enrichment facility.
The initial core supply agreement is intended to support the supply the required first fuel cores for the initial loading of TerraPower's Natrium project in Wyoming
The long-term supply agreement is a 10-year supply agreement of up to a total of 150 metric tons of HALEU, commencing in 2028 through end of 2037.
The Company has two proprietary enrichment technologies – the Aerodynamic Separation Process and the Quantum Enrichment Process. The Company believes that these enrichment technologies can be deployed in a new HALEU facility for considerably lower capital costs, and in much less time, compared to the construction of a uranium enrichment facility using other known methods.

Financing

Contracts

Global

ASP Isotopes Enters Loan And Supply Agreements With TerraPower To Support Construction Of New HALEU Uranium Enrichment Facility In South Africa, Backed By Conditional Financing And 10-Year HALEU Supply Deal For TerraPower's Natrium Plant In Wyoming, While Both Companies Also Explore U.S. Enrichment Facility Opportunities Using ASP's Proprietary Technologies

SARO

StandardAero Announces Secondary Offering Of 30M Shares Of Common Stock By Affiliates Of Carlyle Group And GIC

DLTR

Dollar Tree Appoints Duncan MacNaughton Chairman And Chief Executive Officer

A Reddit <a href="https://www.reddit.com/r/jobs/comments/1kmidby/americans_how_do_you_deal_with_at_will_employment/">thread</a> posted on the r/jobs forum has sparked a surge of frustration, empathy and truth-telling about the harsh reality of &#8220;at-will&#8221; employment in the U.S.
It started with a straightforward question from a person, an employee based outside the U.S., reacting to news of sudden <a href="https://www.benzinga.com/markets/equities/25/05/45398101/microsoft-to-cut-6000-jobs-in-global-restructuring-joins-meta-and-amazon-in-trimming-workforce-amid-ai-driven-shift">layoffs at Microsoft</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>): &#8220;How can you live comfortably knowing that you can be fired at any time and for any reason?&#8221; they asked. &#8220;[In] the country where I'm based, you have to give a valid reason to fire someone.&#8221;
Hundreds of replies poured in from American workers across industries, describing a system that many say creates constant stress, fear and a deep lack of trust in employers.
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
<h2 class="wp-block-heading">&#8216;We Don't Live Comfortably&#8217;</h2>
&#8220;We don't live comfortably,&#8221; wrote one person. &#8220;Every day you have a <a href="https://www.benzinga.com/markets/25/04/44808308/americans-brace-for-job-losses-as-ny-fed-survey-flags-pandemic-era-highs-in-unemployment-worries">fear of losing your job</a>.&#8221;
Another added, &#8220;It&#8217;s why a lot of people tend to casually explore other opportunities even while they&#8217;re employed. I often had calls with recruiters or interviewed for other roles just to stay sharp.&#8221;
A healthcare worker described how management pushed out a colleague of 20 years simply because he didn&#8217;t get along with his new boss. &#8220;She built a bullsh&#x2A;t case over a year and randomly fired him,&#8221; they wrote. &#8220;She blackballed him from ever getting a job in our entire health system.&#8221;
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a>
<h2 class="wp-block-heading">Legal Protection Exists, but Good Luck Using It</h2>
Several commenters pointed out that while there are laws against discriminatory or retaliatory firings, they're nearly impossible to prove and even harder to fight. &#8220;Even if it was for explicitly illegal reasons, we probably couldn&#8217;t afford to take it to court,&#8221; one person wrote.
Another user explained, it&#8217;s legal to fire someone for an illegal reason, as long as you say it was for something else.
And while some suggested that lawyers might work on contingency, many replied that in practice, justice is often out of reach: &#8220;Justice was sealed off [for me],&#8221; one said.
<h2 class="wp-block-heading">Coping Strategies and Workarounds</h2>
Faced with this uncertainty, users shared the various ways they try to cope. For many, that means keeping <a href="https://www.benzinga.com/money/what-is-an-emergency-fund">emergency savings</a>, building hard-to-replace skill sets, and always having an updated resume ready.
&#8220;Make yourself valuable and expensive to replace,&#8221; said an air compressor technician. &#8220;That doesn&#8217;t mean busting your ass. It just means you do your job well and always be looking.&#8221;
See Also: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.&nbsp;
One commenter shared their unique solution: after being laid off twice in a row, they stopped chasing high-paying positions and instead took on <a href="https://www.benzinga.com/news/25/01/43346851/surprisingly-feasible-software-engineer-shares-how-a-175k-second-job-helped-him-save-20k-in-just-two-months">two stable remote jobs that pay more</a> than what they earned before with one job. &#8220;I work them both at the exact same time (9 to 5) and neither knows that the other exists.&#8221;
<h2 class="wp-block-heading">Some Find Comfort in Higher Pay and Flexibility</h2>
A few people defended the &#8220;at-will&#8221; system, arguing that it gives employees the same freedom to quit on the spot and keeps wages higher in a competitive market. As one said, &#8220;It's a better system for those that do well,&#8221; while acknowledging that it can be brutal for others.
For many, though, the risks outweigh the benefits. One summed it up starkly: &#8220;We don&#8217;t deal with it. We suffer it.&#8221; Another said, &#8220;America is a literal dystopia, and it&#8217;s so f&#x2A;&#x2A;&#x2A;ing stressful for everyone but the rich.&#8221;
As for the original poster, they were left stunned by the responses. &#8220;You're very lucky to live where you do,&#8221; replied one American.
Read Next:
<ul class="wp-block-list">
<li>The team behind $6B+ in licensing deals is now building the next billion-dollar IP empire — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">invest early at $2.25/share.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
Image: Shutterstock

Personal Finance

MSFT

A Microsoft Employee From Abroad Questions US Job Security Norms. 'How Can You Live Comfortably Knowing You Can Be Fired At Any Time?'

Marti Technologies Appoints Cenk Özeker As CFO

Stock Split

EKSO

Ekso Bionics Announces 1-For-15 Reverse Stock Split

Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) has outperformed the market over the past 5 years by 1.23% on an annualized basis producing an average annual return of 16.25%. Currently, Expedia Group has a market capitalization of $21.11 billion. 
Buying $1000 In EXPE: If an investor had bought $1000 of EXPE stock 5 years ago, it would be worth $2,148.94 today based on a price of $165.49 for EXPE at the time of writing.
<h3>Expedia Group's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747686615_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

EXPE

$1000 Invested In Expedia Group 5 Years Ago Would Be Worth This Much Today

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/MGWFF">Maple Leaf Green World</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MGWFF#OTC">MGWFF</a>) shares closed up 25.85% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed up 23.48% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed up 18.75% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed up 17.65% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 12.50% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed up 10.03% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed up 9.69% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed up 8.33% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed up 8.16% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed up 5.72% at $7.76</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed up 4.21% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed up 4.18% at $0.71</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed up 4.01% at $0.08</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed up 3.60% at $0.40</li>
<li><a href="https://www.benzinga.com/quote/TCNNF">Trulieve Cannabis</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) shares closed up 3.41% at $4.45</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed down 14.71% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed down 9.49% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed down 8.39% at $0.09</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 8.38% at $0.45</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed down 5.96% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/CRON">Cronos Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>) shares closed down 4.19% at $2.06</li>
<li><a href="https://www.benzinga.com/quote/GBHPF">Global Hemp Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBHPF#OTC">GBHPF</a>) shares closed down 4.17% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/OGI">Organigram Global</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) shares closed down 3.68% at $1.31</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed down 3.23% at $0.01</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

BBRRF

CBDY

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CNTMF

CRBP

CRLBF

CRON

CVSI

CWBHF

FFNTF

FUAPF

GBHPF

GNLN

ITHUF

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LMLLF

LVRLF

MGWFF

MRMD

RMHB

TCNNF

TLRY

UGRO

Cannabis Stock Gainers And Losers From May 19, 2025

On May 17, 2025, the Board of Directors of Verra Mobility Corporation (the "Company") authorized a stock repurchase program to repurchase up to $100 million of its outstanding shares of Class A common stock, par value $0.0001 per share (the "Common Stock"). Under the repurchase program, the Company may purchase shares of Common Stock from time to time until November 13, 2026 through open market purchases, in privately negotiated transactions or by other means, including through trading plans intended to qualify under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, and accelerated share repurchase agreements, each as permitted under applicable rules and regulations. The amount and timing of repurchases will be determined at the Company's discretion and will depend on a variety of factors, including price, general business and market conditions, applicable legal requirements, and alternative investment opportunities.

Buybacks

VRRM

Verra Mobility Authorizes $100M Stock Repurchase Program

The Board of Directors of Vertex Pharmaceuticals Incorporated (the "Company") has authorized an additional program to repurchase up to $4.0 billion of the Company's common stock (the "2025 Repurchase Program"). The 2025 Repurchase Program does not have an expiration date and can be discontinued at any time. Under the 2025 Repurchase Program, the Company may repurchase stock from time to time, subject to general business and market conditions and other investment opportunities, on the open market or through privately negotiated transactions, including through Rule 10b5-1 plans.
 &nbsp;
In 2023, the Company's Board of Directors authorized a program to repurchase up to $3.0 billion of the Company's common stock (the "2023 Repurchase Program"). As of May 16, 2025, the Company had approximately $775 million remaining authorization available under the 2023 Repurchase Program. Between the 2025 Repurchase Program and the 2023 Repurchase Program, the Company is authorized to repurchase up to $4.775 billion of the Company's common stock.

VRTX

Vertex Pharmaceuticals Authorizes $4B Stock Repurchase Program

StandardAero Files For Resale Of Up To 221.64M Shares Of Common Stock By The Selling Stockholders

Press Releases

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Health Care

ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Small Cap

Opinion

Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004,  a Novel EGFR-targeted Antibody-drug Conjugate

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

Comments

ALX Oncology Holdings

Vendite allo scoperto

ALX Oncology Holdings (NASDAQ:ALXO) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO